NEVRO CORP (NVRO)
US64157F1030 - Common Stock
We assign a fundamental rating of 2 out of 10 to NVRO. NVRO was compared to 188 industry peers in the Health Care Equipment & Supplies industry. NVRO has a bad profitability rating. Also its financial health evaluation is rather negative. NVRO is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year NVRO has reported negative net income.
In the past year NVRO has reported a negative cash flow from operations.
In the past 5 years NVRO reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: NVRO reported negative operating cash flow in multiple years.
1.2 Ratios
NVRO has a Return On Assets (-12.84%) which is comparable to the rest of the industry.
NVRO's Return On Equity of -28.25% is in line compared to the rest of the industry. NVRO outperforms 56.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.84% | ||
| ROE | -28.25% | ||
| ROIC | N/A |
ROA(3y)-12.29%
ROA(5y)-13.9%
ROE(3y)-24.6%
ROE(5y)-28.62%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NVRO's Gross Margin of 68.05% is fine compared to the rest of the industry. NVRO outperforms 77.01% of its industry peers.
NVRO's Gross Margin has been stable in the last couple of years.
NVRO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.05% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.39%
GM growth 5Y-0.67%
2. Health
2.1 Basic Checks
NVRO does not have a ROIC to compare to the WACC, probably because it is not profitable.
NVRO has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, NVRO has more shares outstanding
The debt/assets ratio for NVRO is higher compared to a year ago.
2.2 Solvency
NVRO has an Altman-Z score of -0.43. This is a bad value and indicates that NVRO is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of NVRO (-0.43) is comparable to the rest of the industry.
NVRO has a Debt/Equity ratio of 0.80. This is a neutral value indicating NVRO is somewhat dependend on debt financing.
NVRO's Debt to Equity ratio of 0.80 is on the low side compared to the rest of the industry. NVRO is outperformed by 75.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.8 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.43 |
ROIC/WACCN/A
WACC6.88%
2.3 Liquidity
A Current Ratio of 4.77 indicates that NVRO has no problem at all paying its short term obligations.
The Current ratio of NVRO (4.77) is better than 72.19% of its industry peers.
NVRO has a Quick Ratio of 3.53. This indicates that NVRO is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 3.53, NVRO is doing good in the industry, outperforming 68.98% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.77 | ||
| Quick Ratio | 3.53 |
3. Growth
3.1 Past
NVRO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 34.62%, which is quite impressive.
Looking at the last year, NVRO shows a small growth in Revenue. The Revenue has grown by 4.62% in the last year.
Measured over the past years, NVRO shows a small growth in Revenue. The Revenue has been growing by 1.88% on average per year.
EPS 1Y (TTM)34.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%21.54%
Revenue 1Y (TTM)4.62%
Revenue growth 3Y5.51%
Revenue growth 5Y1.88%
Sales Q2Q%-6.69%
3.2 Future
NVRO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.69% yearly.
NVRO is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.12% yearly.
EPS Next Y-8.02%
EPS Next 2Y-1.13%
EPS Next 3Y6.31%
EPS Next 5Y12.69%
Revenue Next Year-4.51%
Revenue Next 2Y-1.07%
Revenue Next 3Y1.33%
Revenue Next 5Y6.12%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
NVRO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NVRO. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.13%
EPS Next 3Y6.31%
5. Dividend
5.1 Amount
NVRO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NEVRO CORP
NYSE:NVRO (11/12/2024, 8:21:57 PM)
After market: 5.1 +0.04 (+0.79%)5.06
-0.26 (-4.89%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap188.64M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -12.84% | ||
| ROE | -28.25% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.05% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.71
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.8 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.77 | ||
| Quick Ratio | 3.53 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)34.62%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-8.02%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)4.62%
Revenue growth 3Y5.51%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y